Protein-bound paclitaxel
| Combination of | |
|---|---|
| Paclitaxel | mitotic inhibitor |
| Albumin | delivery vehicle |
| Clinical data | |
| Trade names | Abraxane |
| AHFS/Drugs.com | FDA Professional Drug Information |
| Pregnancy cat. | ? |
| Legal status | ℞-only (US) |
| Routes | IV |
| Identifiers | |
| ATC code | ? |
 (what is this?) (verify) |
|
Protein-bound paclitaxel is an injectable formulation of paclitaxel, a mitotic inhibitor drug used in the treatment of breast cancer.[1] In this formulation, paclitaxel is bonded to albumin as a delivery vehicle. It is sold in the United States under the trade name Abraxane by Abraxis Bioscience.[2]
This treatment was approved by the Food and Drug Administration in January 2005 for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed.[3]
Abraxane is a first in its class of drugs using nanoparticle albumin bound (nab) technology platform.[4]
In June 2010, positive results were published from a phase III trial in first-line non-small-cell lung cancer (NSCLC) when compared with Taxol (solvent-based paclitaxel).[5]
Total revenue from the sales of Abraxane for 2009 were $314.5 million.[5]
In 2010, Abraxis was acquired by Celgene, who now market Abraxane.[6]
[edit] References
- ^ "Definition of "protein-bound paclitaxel"". National Cancer Institute Dictionary of Cancer Terms. http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=507751.
- ^ "Paclitaxel Albumin-stabilized Nanoparticle Formulation". National Cancer Institute Drug Information. http://www.cancer.gov/cancertopics/druginfo/nanoparticlepaclitaxel.
- ^ "FDA Approval for Nanoparticle Paclitaxel". National Cancer Institute Drug Information. http://www.cancer.gov/cancertopics/druginfo/fda-nanoparticle-paclitaxel.
- ^ nab Technology
- ^ a b "Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC". 2010. http://www.genengnews.com/gen-news-highlights/abraxis-reports-phase-iii-success-with-abraxane-in-first-line-nsclc/81243495/.
- ^ Celgene Completes Acquisition of Abraxis
